摘要
目的探讨卡托普利联合单硝酸异山梨酯缓释片治疗慢性肺原性心脏病心力衰竭的疗效与安全性,以为慢性肺原性心脏病心力衰竭的治疗提供依据。方法选取2007年12月～2009年3月于该院进行治疗的88例慢性肺原性心脏病心力衰竭患者为研究对象,将其随机分为观察组(卡托普利联合单硝酸异山梨酯组)44例和对照组(单硝酸异山梨酯组)44例,后将两组患者的治疗效果、副作用发生率及治疗前后的心肺功能等进行检测分析,并加以统计比较。结果经研究比较发现,观察组的治疗总有效率明显高于对照组(P<0.05),但是副作用发生率与对照组差异无显著性,P>0.05,治疗后观察组患者的FVC%及FEV1%均好于对照组,而观察组SpO2值也高于对照组(P<0.05)。结论采用卡托普利联合单硝酸异山梨酯缓释片在慢性肺原性心脏病心力衰竭的治疗中效果明显,安全可靠,值得临床应用。
【Objective】To study the safety and efficacy on captopril combined with isosorbide mononitrate sustained release tablets in the patients with heart failure induced by chronic pneumocardial disease,in order to provide evidence for the treatment.【Method】88 cases patients with heart failure induced by chronic in our hospital from December 2007 to March 2009 were selected as research object,and were divided observation group（captopril combined with isosorbide mononitrate group） 44 cases and control group（isosorbide mononitrate group） 44 cases.Then the efficacy,incidence of side effects and cardiopulmonary function before and after the treatment were tested,and the results were compared.【Result】After the comparison,it showed that the efficacy of observation group was better than that of control group,P0.05,but the incidence of side effects of the both groups had no difference,P0.05,the FVC% and FEV1% of observation group after the treatment were better than that of control group,and the SpO2 of observation group were higher,P0.05.【Conclusion】The safety and efficacy on captopril combined with isosorbide mononitrate sustained release tablets in the patients with heart failure induced by chronic pneumocardial disease are better,and it is worth of further studying and using.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2010年第7期1076-1078,共3页
China Journal of Modern Medicine
关键词
卡托普利
单硝酸异山梨酯
慢性肺原性心脏病心力衰竭
疗效
安全性
captopril
isosorbide mononitrate
heart failure induced by chronic pneumocardial disease
safety
efficacy
